|Bid||32.50 x 800|
|Ask||33.95 x 800|
|Day's Range||32.10 - 33.86|
|52 Week Range||11.65 - 75.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.67|
For investors, news on their progress could cause some drug stocks to be volatile. Among antibody developers, Vir Biotechnology has the most to gain.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
(Bloomberg Opinion) -- As companies and countries pour money into the effort to develop Covid-19 vaccines, timelines keep getting more ambitious and dates for delivering a workable immunization against the virus keep moving up. Yet even with companies such as Moderna Therapeutics Inc. and AstraZeneca Plc signaling rapid progress and already enrolling patients in mid-stage trials, it would be quite a feat if we had a stockpile of proven doses by year's end. That’s a best-case scenario. A longer wait is more likely, and that may seem discouraging. The good news is, there is a batch of treatments in development with a chance of accelerated approval, and they can provide needed relief in the interim.Dozens of approaches could serve as a valuable bridge, from repurposed drugs to bespoke antibody cocktails. None can replace the value of a vaccine in getting the world back to normal, but the availability of more treatment options for sick patients could help to increase the chances of a faster and fuller recovery, and reduce the lethality of the disease. Two of the most familiar treatments options — the malaria drug hydroxychloroquine and Gilead Sciences Inc.’s remdesivir — have recently run into issues over safety and degree of efficacy, but there are plenty more in the pipeline.When it comes to development, the pathway for treatments is generally smoother than the one for vaccines, which can run into bottlenecks that are fundamentally difficult to break. For one, the fact that innoculations are aimed at healthy individuals means there is a higher safety bar. And the large trials necessary for trying out vaccines would have to occur in places where Covid-19 is spreading substantially to get the random exposure required to test them properly. With multiple candidates in development and ongoing precautions to avoid infection, getting robust data fast may be an issue. Finding volunteers is also an issue for treatment trials, as case counts level off. Still, many outcomes for infected patients can be determined comparatively rapidly. Along with a higher tolerance for side effects in individuals at possible near-term risk of dying, this permits smaller and faster tests.There are a few significant groups of possible treatments. The first involves repurposing existing drugs such as hydroxychloroquine and remdesivir. Because these types of medicines were originally designed to treat other conditions, they are less likely to produce a dramatic effect. However, if one is useful, it can be deployed quickly.One category within this group doesn't aim at the virus, but the out-of-control immune response it can cause. Roche Holding AG's arthritis drug Actemra has shown some early promise and is in larger trials. Researchers plan to test a variety of other medicines that target inflammation. If successful, they could provide several avenues to improved outcomes in critically ill patients. Another idea? Drug cocktails. That's the thought behind a recently started trial combining remdesivir and Actemra. Several other repurposed combinations, existing flu drugs, and a host of other medicines have opportunities to prove their worth.A second category of drug treatments involves a different type of recycling: using the blood of recovered individuals. People who survive Covid-19 develop antibodies against the virus and their donated plasma is already part of treatment regimens for sick patients around the world. Early results look promising, but they need confirmation from randomized trials that are now under way. Scale and variability issues may prevent convalescent plasma from treating millions, so it's worth boosting identification and collection efforts now even if the benefits of this type of treatment aren’t yet fully determined. A concentrated version under development by Takeda Pharmaceutical Co. also could prove useful.A related third group of medicines centers on artificially produced antibodies, which could be more effective and available than natural counterparts. Companies including Eli Lilly & Co., Regeneron Pharmaceuticals Inc. and Vir Biotechnology Inc. are pursuing this approach. Lilly announced the start of its first trial Monday. Regeneron, which created a successful antibody cocktail for an Ebola epidemic, is right behind. While there's no guarantee of success, these treatments have a better chance of autumn availability than even the fastest vaccines. It would take additional trials to confirm, but this category has particular value as a bridge because it can function as both treatment and temporary protection.Unless making and deploying hundreds of millions of inoculations is a lot easier than I expect and the fastest vaccines durably prevent both infection and transmission — a big ask for warp-speed efforts — Covid-19 may be around in diminished form for a while to come. That means treatments will remain valuable even after vaccines arrive. The more tools doctors have, the better.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising.
Gilead's stock has posted consistent growth this year as a result of its ambitious antiviral drug development program for COVID-19. With the preliminary publication of favorable clinical trial results for Gilead's remdesivir antiviral, the company cemented its earlier growth for the short term. On Thursday, Roche revealed that it was testing Gilead's remdesivir as part of a combination therapy for COVID-19, a move which will doubtlessly be followed by others in the coming weeks.
Vir Biotechnology, Inc. (VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (BIIB) based on the letter of intent that the companies announced in March. Under the agreement Biogen will perform process development activities and specified manufacturing and process transfer services to enable commercial supply of Vir’s SARS-CoV-2 monoclonal antibodies.
Vir Biotechnology, Inc. (VIR) today announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody that neutralizes hepatitis B virus (HBV) and has been engineered to potentially also act as a therapeutic vaccine. VIR-3434 is an HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes, and also to reduce the level of virions and subviral particles in the blood.
These biotech companies are both infectious disease experts and are likely to remain in the forefront when it comes to coronavirus treatment.
At its worst on March 23rd, Dow Jones and the S&P declined by around 37% and 34%. At the time, those kinds of numbers represented a loss of a 3-year gain since Trump’s election in November of 2016. Measured by VIX, market volatility spiked by 43% in March, reaching levels that are comparable to the […]
Shares of Vir Biotechnology (NASDAQ: VIR) soared on Monday after the company announced some exciting news regarding its efforts to develop a treatment for COVID-19. Specifically, promising research findings from Vir's attempts to defeat COVID-19 were published in a paper in the journal Nature, one of the world's leading science journals. Vir's stock closed the day up by 32.1%.
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
Vir Biotechnology, Inc. (VIR) today announced the publication of research findings from the company’s efforts to develop therapeutics for COVID-19 in the May 18, 2020 issue of the journal Nature. The paper, entitled “Cross-neutralization of SARS-CoV and SARS-CoV2 by a human monoclonal antibody” (Pinto, et al., Nature), details the identification and characterization of S309, an antibody isolated from a patient who recovered from severe acute respiratory syndrome (SARS) in 2003, which has been shown to prevent SARS-CoV-2 live virus infection of cells. Vir is advancing two clinical development candidates based on the S309 antibody as potential therapeutics for COVID-19, VIR-7831 and VIR-7832, in collaboration with GlaxoSmithKline plc (LSE/NYSE: GSK).
Trump revealed the newest plans to develop vaccine, but later said the country will make a comeback with or without it. Board Certified Specialist in Preventive Medicine & Public Health Dr. David Katz joins Yahoo Finance’s Seana Smith to discuss.
Vir Biotechnology, Inc. (NASDAQ:VIR) came out with its quarterly results last week, and we wanted to see how the...
SAN FRANCISCO, May 12, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.
Vir Biotechnology, Inc. (VIR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Vir Biotechnology, Inc. is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio webcast. Stockholders will not be able to attend the Annual Meeting in person. Vir Biotechnology’s stockholders of record as of March 27, 2020 (the “Record Date”) can attend the Annual Meeting by accessing the meeting center at http://www.virtualshareholdermeeting.com/VIR2020 and entering the 16-digit control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received.
SAN FRANCISCO, May 07, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.
Clinical Professor of Epidemiology at NYU School of Global Public Health Dr. Robyn Gershon joins Yahoo Finance’s Seana Smith to discuss the latest coronavirus developments as more states gear up to implement reopening plans.
JP Morgan Private Bank Head of Cross-Asset Thematic Strategy Anastasia Amoroso joins Yahoo Finance’s Seana Smith to discuss the latest market action as more states move to reopen their economies in the wake of the coronavirus.
The companies plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss accelerating their filing for starting the trials of the inhaled therapy. Shares of Vir Biotech climbed 4% to $29, while Alnylam's stock rose 1.6% to $131 in premarket trading.
Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the selection of a development candidate (DC) for VIR-2703 (also referred to as ALN-COV), an investigational RNAi therapeutic targeting the SARS-CoV-2 genome. The companies plan to soon meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss a potential accelerated path for filing an Investigational New Drug (IND) or IND equivalent application at or around year-end 2020, less than a year since program initiation. The companies plan to advance VIR-2703 as an inhalational formulation for the potential treatment and/or prevention of COVID-19.
SAN FRANCISCO, April 28, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases,.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 15.) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * Calithera Biosciences Inc (NASDAQ: CALA) (provided an update on the impact of COVID-19 on its ongoing clinical trials) * Eli Lilly And Co (NYSE: LLY) * Keros Therapeutics Inc (NASDAQ: KROS) (went public April 8) * Masimo Corporation (NASDAQ: MASI) * Moderna Inc (NASDAQ: MRNA (analysts hiked price targets for the shares following the company's Virtual Vaccines Day) * Pluristem Therapeutics Inc. (NASDAQ: PSTI) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)Down In The Dumps (Biotech stocks that hit 52-week lows April 15.) * Akorn, Inc. (NASDAQ: AKRX) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * TherapeuticsMD Inc (NASDAQ: TXMD) * Vaccinex Inc (NASDAQ: VCNX) * Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Stocks In Focus UroGen's Kidney Cancer Drug Gets FDA Approval Urogen Pharma Ltd (NASDAQ: URGN) said the FDA granted expedited approval for its Jelmyto for pyelocaliceal solution, indicated to treat adults with low-grade upper tract urothelial cancer. The company said the approval was granted based on positive results from a Phase 3 Olympus trial that demonstrated Jelmyto's effectiveness in this rare and difficult-to-treat cancer.Jelmyto consists of mitomycin, an established chemotherapy and sterile hydrogel, using Urogen's proprietary sustained release RTGel technology.The stock was trading more than 14% higher at $24 in Thursday's premarket session. Accelerate Diagnostics Pre-Announces In-Line Q1 Revenue Accelerate Diagnostics Inc (NASDAQ: AXDX) said it expects first-quarter net sales of $2.3 million, higher than $1.8 million in the year-ago period and in line with the consensus estimate.Citing the uncertainty surrounding the duration of the COVID-19 pandemic, the company withdrew its guidance.The stock rallied 7.89% to $9.02 in after-hours trading.Vanda To Study Impact Of Human Genetic Variations On Coronavirus Infection, Progression Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced the initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 infection and disease progression. The company said it will collaborate with the University of Washington School of Medicine and its Virology Lab on a pharmacogenetics study in COVID-19 patients."The study will focus on the sequencing of the genome of individual patients, as well as the COVID-19 virus, and the identification of genetic factors that correlate with disease progression and outcomes," according to Vanda. Separately, Vanda said it has enrolled the first patient in its ODYSSEY trial at Lenox Hill Hospital in New York City with Northwell Health's research arm. The ODYSSEY trial is a Phase 3 study investigating the efficacy and safety of tradipitant, a neurokinin-1 receptor antagonist, in the treatment of neurogenic inflammation of the lung secondary to SARS-CoV-2 infection.The stock was trading 8.45% higher at $11.30 in Thursday's premarket session. See also: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates Vir Presents Positive Data For Hepatitis B Virus Drug Vir Biotechnology Inc (NASDAQ: VIR) announced additional interim data from the ongoing Phase 2 study and results from the Phase 1 trial in healthy volunteers of VIR-2218, an investigational small interfering ribonucleic acid that mediates RNA interference for the treatment of chronic hepatitis B virus infection.The company said interim results from the Phase 2 study showed VIR-2218 resulted in a significant dose-dependent and durable reduction in hepatitis B surface antigen through week 24 in patients who received two doses ranging from 20 mg to 200 mg.Vir had licensed the investigational asset from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Vir said it will initiate combination trials of VIR-2218 with a shortened course of pegylated interferon, with dosing likely to begin in the second half of 2020.Vir shares were trading 0.79% higher at $29.50 in the premarket session. Co-Diagnostics Says COVID-19 Tests Validated For Use With Saliva Samples Co-Diagnostics Inc (NASDAQ: CODX) said OralDNA Labs, a CLIA-certified laboratory, recently validated a COVID-19 PCR test based on the its patented CoPrimer technology for use with saline oral rinse samples, and has notified the FDA of their intent to use the validated test in their CAP accredited high-complexity laboratory.The stock was adding 7.16% to $10.18 in premarket trading. Soligenix Licenses COVID-19 Vaccine Adjuvant From Boston Scientific Unit Soligenix, Inc. Common Stock (NASDAQ: SNGX) announced an agreement for exclusive worldwide licensing of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corporation (NYSE: BSX), for SARS-CoV-2.View more earnings on IBBThe stock was ripping higher by 60% to $2.24 in premarket trading. Eagle Pharma Submits IND For Coronavirus Treatment Candidate Eagle Pharmaceuticals Inc (NASDAQ: EGRX) said its Ryanodex for injectable suspension inhibited the growth of SARS-CoV-2 in lab tests. The company said it submitted an IND to the FDA for a Phase 2 clinical trial in partnership with Hackensack University Medical Center to evaluate the efficacy of Ryanodex in patients infected with the virus.Inovio Nets $6.9M In Funding To Initiate South Korean Clinical Trial Of Coronavirus Vaccine Candidate Inovio Pharmaceuticals Inc (NASDAQ: INO) has been granted $6.9 million in funding by the Coalition for Epidemic Preparedness Innovations to work with the International Vaccine Institute and the Korea National Institute of Health for a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine candidate INO-4800 in South Korea, according to the IVI. The organization said it will conduct the trial in South Korea.In premarket trading Thursday, Inovio shares were advancing 7.84% to $7.70.Ascendis' Growth Hormone Deficiency Drug Granted Orphan Drug Designation Ascendis Pharma A/S (NASDAQ: ASND) said the FDA has granted Orphan Drug Designation to its TransCon hGH as a treatment for growth hormone deficiency.AEterna Warned On Nasdaq Listing Standards, Has 180-Day Grace Period To Regain Compliance AEterna Zentaris Inc. (NASDAQ: AEZS) said it has received notice from Nasdaq indicating the company is not in compliance with the minimum $1-per-share bid price requirement, having closed below $1 per share for the prior 30 consecutive business days. The company said it has been provided a grace period of 180 calendar days through Oct. 5 to regain compliance.Novavax Coronavirus Vaccine To Enter Clinics In Australia Novavax, Inc.'s (NASDAQ: NVAX) Australian development partner Nucleus Network said it is due to commence Phase 1 testing of the former's NVX-CoV2372, a SARS-CoV-2 recombinant spike protein nanoparticle vaccine, at its Melbourne and Brisbane clinics in the coming weeks.In premarket trading Thursday, Novavax shares were adding 2.51% to $17.97. Offerings Calithera said it has priced its underwritten public offering of 5 million shares at $6.25 per share. The company expects to raise gross proceeds of $31.25 million from the offering. The offering is expected to close April 20.The stock was down 1.18% to $7.51 in the premarket session. Arcturus Therapeutics Ltd (NASDAQ: ARCT), which recently issued an update on its COVID-19 vaccine development program, said it intends to sell shares of its common stock in an underwritten public offering. All the shares are to be offered by the company.The company said it intends to use the net proceeds for working capital and general corporate purposes, including capex and R&D expenses related to the advancement of its LUNAR-OTC, LUNAR-COV19 and its other product candidates and clinical trial expenditures.The stock was down 3.06% at $17.45 in the premarket session. Athersys Inc (NASDAQ: ATHX) said it intends to offer $50 million of its common stock for sale in an underwritten public offering. The company said it will use the net proceeds for working capital and general corporate purposes, including funding its acute respiratory distress syndrome clinical program, which includes initiation of a Phase 2/3 pivotal study for COVID-19-induced ARDS patients, and its process development and manufacturing projects.The stock was down 25.81% at $2.30 in the premarket session. On The Radar Clinical Readouts Moleculin Biotech Inc (NASDAQ: MBRX) is hosting a web-based investor conference call at 4:30 p.m. ET Thursday to explain the significance of the recent discovery that the active compound in its WP1122 drug candidate, which it has licensed to WPD Pharmaceuticals Inc (OTC: WCOTF), has been shown to reduce replication of SARS-CoV-2 by 100%.Earnings Thursday Abbott Laboratories (NYSE: ABT) (before the market open)Intuitive Surgical, Inc. (NASDAQ: ISRG) (after the close)Related Link:Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use See more from Benzinga * 3 Frontrunners In COVID-19 Vaccine Development: What You Need To Know * The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US * The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.